These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18669449

  • 1. Challenges and pitfalls of combining targeted agents in phase I studies.
    Cannistra SA.
    J Clin Oncol; 2008 Aug 01; 26(22):3665-7. PubMed ID: 18669449
    [No Abstract] [Full Text] [Related]

  • 2. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
    Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC.
    J Clin Oncol; 2008 Aug 01; 26(22):3709-14. PubMed ID: 18669456
    [Abstract] [Full Text] [Related]

  • 3. Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
    Schultheis B, Neumann H, Roy R, Heuer V, Kummer G, Strumberg D.
    Int J Clin Pharmacol Ther; 2012 Jan 01; 50(1):72-3. PubMed ID: 22192652
    [No Abstract] [Full Text] [Related]

  • 4. [Oncology 2008].
    Stemmler HJ, Heinemann V.
    Dtsch Med Wochenschr; 2008 Jun 01; 133(25-26):1395-9. PubMed ID: 18521794
    [No Abstract] [Full Text] [Related]

  • 5. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch, Budak K, Pestalozzi B.
    Praxis (Bern 1994); 2011 Jul 27; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract] [Full Text] [Related]

  • 6. It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
    Boere IA, Hamberg P, Sleijfer S.
    Cancer Sci; 2010 Jan 27; 101(1):7-15. PubMed ID: 19860846
    [Abstract] [Full Text] [Related]

  • 7. [Targeted therapies and their indications in solid neoplasias].
    Dreyer C, Raymond E, Faivre S.
    Rev Med Interne; 2009 May 27; 30(5):416-24. PubMed ID: 19299048
    [Abstract] [Full Text] [Related]

  • 8. Design of clinical trials of radiation combined with antiangiogenic therapy.
    Senan S, Smit EF.
    Oncologist; 2007 Apr 27; 12(4):465-77. PubMed ID: 17470689
    [Abstract] [Full Text] [Related]

  • 9. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U, interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG).
    Aktuelle Urol; 2009 Jan 27; 40(1):27-30. PubMed ID: 19177318
    [Abstract] [Full Text] [Related]

  • 10. Targeting angiogenesis in bladder cancer.
    Elfiky AA, Rosenberg JE.
    Curr Oncol Rep; 2009 May 27; 11(3):244-9. PubMed ID: 19336017
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
    Snider KL, Maitland ML.
    Target Oncol; 2009 Apr 27; 4(2):67-76. PubMed ID: 19373440
    [Abstract] [Full Text] [Related]

  • 12. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC, Fernandes Gdos S, Kann AG, Aguilar-Ponce JL, de la Garza J, Buzaid AC.
    Cancer Treat Rev; 2008 Dec 27; 34(8):750-60. PubMed ID: 18801619
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
    Lee JM, Sarosy GA, Annunziata CM, Azad N, Minasian L, Kotz H, Squires J, Houston N, Kohn EC.
    Br J Cancer; 2010 Feb 02; 102(3):495-9. PubMed ID: 20051952
    [Abstract] [Full Text] [Related]

  • 14. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC.
    Cancer; 2008 Apr 15; 112(8):1726-32. PubMed ID: 18300236
    [Abstract] [Full Text] [Related]

  • 15. Phase I studies of drug combinations.
    Verweij J, Disis ML, Cannistra SA.
    J Clin Oncol; 2010 Oct 20; 28(30):4545-6. PubMed ID: 20855831
    [No Abstract] [Full Text] [Related]

  • 16. Recent advances in the systemic treatment of metastatic papillary renal cancer.
    Chowdhury S, Choueiri TK.
    Expert Rev Anticancer Ther; 2009 Mar 20; 9(3):373-9. PubMed ID: 19275514
    [Abstract] [Full Text] [Related]

  • 17. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Gschwend J, Jäger E, Keilholz U.
    Aktuelle Urol; 2010 May 20; 41(3):193-6. PubMed ID: 20486036
    [Abstract] [Full Text] [Related]

  • 18. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
    Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.
    J Exp Clin Cancer Res; 2010 Jul 14; 29(1):95. PubMed ID: 20630084
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
    Marsh AM, Lo L, Cohen RA, Feusner JH.
    Pediatr Blood Cancer; 2012 Nov 14; 59(5):939-40. PubMed ID: 22492703
    [Abstract] [Full Text] [Related]

  • 20. Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
    Leguerney I, Lassau N, Koscielny S, Rodrigues M, Massard C, Rouffiac V, Benatsou B, Thalmensi J, Bawa O, Opolon P, Peronneau P, Roche A.
    Invest New Drugs; 2012 Feb 14; 30(1):144-56. PubMed ID: 20924644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.